PharmaDing Live Session: '2026 Dialogue with New Drug Founders on AI for Science (AI4S)'
ChemPartner
Contract Research and Manufacturing Organization (CRMO)
PHIL RIVERS
Medical Information Technology Service Provider
Currently, biopharmaceutical R&D is undergoing a profound paradigm shift driven by artificial intelligence and automation technologies. Rising R&D costs, bottlenecks in clinical success rates, and the urgent need to break through traditional discovery models have created a demand for smarter, more efficient, and more predictable new R&D systems. Against this backdrop, ChemPartner has proactively proposed the "New Intelligent Productivity" strategy, aiming to use AI and data as core engines to reconstruct the entire chain from target discovery to candidate compound optimization, advancing R&D from "experience-driven" to "computation-driven" and "intelligence-driven."
During this period of transformative change, the founders of new drugs are both explorers of cutting-edge science and key drivers of innovation in research and development models.
The core propositions they face include: How to build a differentiated R&D pipeline with computational attributes? How to deeply integrate AI into early discovery and translational research? How to enhance the "intelligent density" of the team while controlling costs? And how to effectively collaborate with "new intelligent productivity" enabling platforms like ChemPartner to accelerate the process from concept to clinical trials?
To this end, Yaodingji and ChemPartner jointly invitedPHIL RIVERS Co-Founder Zhao Yu, Ningbo Junjian Biotechnology Co., Ltd.CEO Xiong Changyun, Founder of Hangzhou Aomo Pharmaceuticals Qi Youmao, Chairman of ChemPartner Hu Ruilian, and Senior Director of ChemPartner Xu YuzhouYuApril 24, 2026Day19:00Be a GuestPharmaceutical Cauldron RecordsOnline Live Broadcast RoomEngage in in-depth discussions to provide strategic references that combine thought leadership and practical value for new drug founders, jointly advancing China's innovative drug development into the "New Intelligence" era.
Scan to follow【Pharmaceutical Cauldron Records】
Click to schedule a reminder and don't miss out.
ChemPartner (A-share Code: 300149.SZ), established in 2000 and headquartered in the core Zhangjiang area of Shanghai, China, is an innovative enterprise (CRO/CDMO) dedicated to integrated services for new drug research, development, and production. The company’s business network spans globally, with offices, R&D centers, and production bases located in Zhangjiang and Jinqiao in Shanghai, Lingang New Area, Qidong in Jiangsu, Chengdu in Sichuan, Guangzhou in Guangdong, South Boston in the United States, and Copenhagen in Denmark. It provides comprehensive, end-to-end services covering the entire lifecycle of new drug development, from early discovery to commercial production, for both small molecule and biologic drugs, serving global pharmaceutical companies, biotechnology firms, and research institutions. ChemPartner has established strategic partnerships with over 150 top global biopharmaceutical research organizations and enterprises and has provided scientific research services to nearly 4,000 global pharmaceutical and biotechnology companies, encompassing almost all of the top 20 multinational pharmaceutical corporations worldwide.
PRHub of Yaorong Circle aims to assist biopharmaceutical technology enterprises in brand promotion and business development services. It provides systematic solutions based on customers' real needs, and uses "translation-simplification-contextualization" to make the brand information easily understood by the public. With over 1 million vertical users across traffic channels, it achieves cooperation goals while helping partners complete a closed-loop marketing service from branding to business. We have successfully organized dozens of offline biopharmaceutical R&D conferences with 1,000+ attendees, covering small-molecule new drugs, large-molecule new drugs, improved new drugs, and BD cross-border transactions. Our branded conferences include the China International Biopharmaceutical & Chemical Pharmaceutical Industry Conference (6,000+ attendees), the Generic Drug Summit (600+ attendees), and the New Drug Innovators Series Summit (1,200+ attendees). We have served over a hundred listed/unicorn/biotech/pharmaceutical companies.